BioNTech

BioNTech启动10亿美元回购与1800人裁员：下半年7项关键临床数据待揭晓

BioNTech的估值岔路口：巨额现金回购与临床数据能否弥合分析师分歧？

angelina -

BioNTech’s Pipeline Grows Faster Than Its Stock, Leaving a 36% Analyst Upside on the Table

kashif hafeez -

BioNTech转型阵痛：172亿欧元现金在手，市场为何仍给“折扣价”？

BioNTech’s Radical Pivot: Inside the Founder Exit, 1,860 Job Cuts and a $17 Billion Cancer Wager

Brett Shapiro -

BioNTech核心研发团队出走：一场从新冠王者到肿瘤新贵的“断腕式”转型

kashif hafeez -

BioNTech祭出10亿美元回购牌：股价深跌下的自救与肿瘤管线新叙事

BioNTech’s Board Expansion Signals Oncology Pivot — But the Market Still Wants Proof

angelina -

76欧元关口博弈：BioNTech的”数据沉默期”遇上EHA与宏观风暴

kashif hafeez -

BioNTech Caught in mRNA Sector Jolt as $590M Moderna Contract Cut Adds to Pipeline Transition Pain

BioNTech：千亿现金回购遇上德国改革暗流，肿瘤管线能否撬动估值重塑？

angelina -

BioNTech’s $1 Billion Buyback Fails to Lift Stock as German Reform Threat and Pipeline Wait Drag On

kashif hafeez -

BioNTech ASCO亮出双抗王牌：Pumitamig缓解率100%跌破眼镜，副作用比Keytruda更轻

kashif hafeez -

BioNTech’s Cancer Pivot Faces Dual Headwinds: Berlin’s Vaccine Demands and Founder Exit

BioNTech告别新冠时代：创始人2026年离场，肿瘤管线接棒

Brett Shapiro -
123...9Page 1 of 9